Lanean...
Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer
Enhancer of zeste homolog 2 (EZH2) is abnormally highly expressed in pancreatic cancer (PC). However, it is not ideal to treat PC by inhibiting EZH2. This study reported that the combined use of pan-peroxisome proliferator-activated receptor (PPAR) agonist could significantly improve the anti-PC eff...
Gorde:
| Argitaratua izan da: | PPAR Res |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Hindawi
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8321753/ https://ncbi.nlm.nih.gov/pubmed/34335707 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2021/5589342 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|